Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss

Eye and Vision

Volumn 2, Issue 1, 2015, Pages

  Lee, Ryan ^a,b   Wong, Tien Y ^a,b,c   Sabanayagam, Charumathi ^a,b,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Epidemiology; Risk factors

Indexed keywords

EID: 85132189046     PISSN: None     EISSN: 23260254     Source Type: Journal    
DOI: 10.1186/s40662-015-0026-2     Document Type: Review

References (216)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. DOI: 10.1016/S0140-6736(09)62124-3
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–49. DOI: 10.1016/S2214-109X(13)70113-X
3. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. DOI: 10.2337/dc11-1909
4. Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003;5(2):12–21. DOI: 10.1016/S1098-3597(03)90015-9
5. Tong L, Vernon SA, Kiel W, Sung V, Orr GM. Association of macular involvement with proliferative retinopathy in type 2 diabetes. Diabet Med. 2001;18(5):388–94. DOI: 10.1046/j.1464-5491.2001.00483.x
6. He F, Xia X, Wu XF, Yu XQ, Huang FX. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. Diabetologia. 2013;56(3):457–66. DOI: 10.1007/s00125-012-2796-6
7. Hagg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM, et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013;36(12):4140–6. DOI: 10.2337/dc13-0669
8. Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. J Diabetes Complications. 2014;28(6):874–9. DOI: 10.1016/j.jdiacomp.2014.07.001
9. Kawasaki R, Tanaka S, Tanaka S, Abe S, Sone H, Yokote K, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology. 2013;120(3):574–82. DOI: 10.1016/j.ophtha.2012.08.029
10. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2015;99(1):64–8. DOI: 10.1136/bjophthalmol-2013-304017
11. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. Ophthalmic Epidemiol. 2010;17(4):251–65. DOI: 10.3109/09286586.2010.498661
12. Hautala N, Hannula V, Palosaari T, Ebeling T, Falck A. Prevalence of diabetic retinopathy in young adults with type 1 diabetes since childhood: the Oulu cohort study of diabetic retinopathy. Acta Ophthalmol. 2014;92(8):749–52. DOI: 10.1111/aos.12426
13. Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, et al. Tromso eye study: prevalence and risk factors of diabetic retinopathy. Acta Ophthalmol. 2013;91(8):716–21. DOI: 10.1111/j.1755-3768.2012.02542.x
14. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The north Jutland county diabetic retinopathy study: population characteristics. Br J Ophthalmol. 2006;90(11):1404–9. DOI: 10.1136/bjo.2006.093393
15. Dedov I, Maslova O, Suntsov Y, Bolotskaia L, Milenkaia T, Besmertnaia L. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. Rev Diabet Stud. 2009;6(2):124–9. DOI: 10.1900/RDS.2009.6.124
16. Roy MS, Klein R, O’Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004;122(4):546–51. DOI: 10.1001/archopht.122.4.546
17. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–63. DOI: 10.1001/archopht.122.4.552
18. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56. DOI: 10.1001/jama.2010.1111
19. Kung K, Chow KM, Hui EM, Leung M, Leung SY, Szeto CC, et al. Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. BMC Fam Pract. 2014;15:8. DOI: 10.1186/1471-2296-15-8
20. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008–2011. Invest Ophthalmol Vis Sci. 2013;54(10):6827–33. DOI: 10.1167/iovs.13-12654
21. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetics study report 2. Ophthalmology. 2009;116(2):311–8. DOI: 10.1016/j.ophtha.2008.09.010
22. Liu L, Wu X, Liu L, Geng J, Yuan Z, Shan Z, et al. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. PLoS One. 2012;7(9):e45264. DOI: 10.1371/journal.pone.0045264
23. Huang OS, Tay WT, Ong PG, Sabanayagam C, Cheng CY, Tan GS, et al. Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study. Br J Ophthalmol. 2015.
24. Zheng Y, Lamoureux EL, Lavanya R, Wu R, Ikram MK, Wang JJ, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology. 2012;119(10):2119–24. DOI: 10.1016/j.ophtha.2012.04.027
25. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46(7):2328–33. DOI: 10.1167/iovs.05-0019
26. Al Ghamdi AH, Rabiu M, Hajar S, Yorston D, Kuper H, Polack S. Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia. Br J Ophthalmol. 2012;96(9):1168–72. DOI: 10.1136/bjophthalmol-2012-301874
27. Papakonstantinou E, Tsinopoulos I, Dimitrakos S, Dehghan MH, Katibeh M, Ahmadieh H, et al. Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: the Yazd Eye Study. J Diabetes. 2015;7(1):139–41. DOI: 10.1111/1753-0407.12205
28. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116(3):461–7. DOI: 10.1016/j.ophtha.2008.10.003
29. Raman R, Ganesan S, Pal SS, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic retinopathy in rural India. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study III (SN-DREAMS III), report no 2. BMJ Open Diabetes Res Care. 2014;2(1):e000005. DOI: 10.1136/bmjdrc-2013-000005
30. Katulanda P, Waniganayake YC, Ranasinghe P, Wijetunga WU, Jayaweera M, Wijesinghe NP, et al. Retinopathy among young adults with diabetes mellitus from a tertiary care setting in Sri Lanka. BMC Endocr Disord. 2014;14:20. DOI: 10.1186/1472-6823-14-20
31. Akhter A, Fatema K, Ahmed SF, Afroz A, Ali L, Hussain A. Prevalence and associated risk indicators of retinopathy in a rural Bangladeshi population with and without diabetes. Ophthalmic Epidemiol. 2013;20(4):220–7. DOI: 10.3109/09286586.2013.809770
32. Thapa R, Joshi DM, Rizyal A, Maharjan N, Joshi RD. Prevalence, risk factors and awareness of diabetic retinopathy among admitted diabetic patients at a tertiary level hospital in Kathmandu. Nepal J Ophthalmol. 2014;6(11) doi: 10.3126/nepjoph.v6i1.10760.
33. Kahloun R, Jelliti B, Zaouali S, Attia S, Ben Yahia S, Resnikoff S, et al. Prevalence and causes of visual impairment in diabetic patients in Tunisia, North Africa. Eye (Lond). 2014;28(8):986–91. DOI: 10.1038/eye.2014.131
34. Mathenge W, Bastawrous A, Peto T, Leung I, Yorston D, Foster A, et al. Prevalence and correlates of diabetic retinopathy in a population-based survey of older people in Nakuru, Kenya. Ophthalmic Epidemiol. 2014;21(3):169–77. DOI: 10.3109/09286586.2014.903982
35. Sharew G, Ilako DR, Kimani K, Gelaw Y. Prevalence of diabetic retinopathy in Jimma University Hospital, Southwest Ethiopia. Ethiop Med J. 2013;51(2):105–13.
36. Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications. 2012;26(2):123–8. DOI: 10.1016/j.jdiacomp.2012.02.001
37. Kostev K, Rathmann W. Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia. 2013;56(1):109–11. DOI: 10.1007/s00125-012-2742-7
38. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26(6):1731–7. DOI: 10.2337/diacare.26.6.1731
39. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008;115(11):1869–75. DOI: 10.1016/j.ophtha.2008.05.014
40. Looker HC, Nyangoma SO, Cromie D, Olson JA, Leese GP, Black M, et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia. 2012;55(9):2335–42. DOI: 10.1007/s00125-012-2596-z
41. Klein R, Klein BK, Moss SE, Davis MD, DeMets DL. The wisconsin epidemiologic study of diabetic retinopathy: Ix. four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107(2):237–43. DOI: 10.1001/archopht.1989.01070010243030
42. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112(9):1217–28. DOI: 10.1001/archopht.1994.01090210105023
43. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801–15. DOI: 10.1016/S0161-6420(98)91020-X
44. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–68. DOI: 10.1016/j.ophtha.2008.08.023
45. Broe R, Rasmussen ML, Frydkjaer-Olsen U, Olsen BS, Mortensen HB, Peto T, et al. The 16-year incidence, progression and regression of diabetic retinopathy in a young population-based Danish cohort with type 1 diabetes mellitus: The Danish cohort of pediatric diabetes 1987 (DCPD1987). Acta Diabetol. 2014;51(3):413–20. DOI: 10.1007/s00592-013-0527-1
46. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabet Med. 2003;20(9):758–65. DOI: 10.1046/j.1464-5491.2003.01035.x
47. Martin-Merino E, Fortuny J, Rivero-Ferrer E, Garcia-Rodriguez LA. Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One. 2014;9(6):e100283. DOI: 10.1371/journal.pone.0100283
48. Kyto JP, Harjutsalo V, Forsblom C, Hietala K, Summanen PA, Groop PH. Decline in the cumulative incidence of severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2011;34(9):2005–7. DOI: 10.2337/dc10-2391
49. Thomas RL, Dunstan F, Luzio SD, Roy Chowdury S, Hale SL, North RV, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the diabetic retinopathy screening service for wales: retrospective analysis. BMJ. 2012;344:e874. DOI: 10.1136/bmj.e874
50. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361(9353):195–200. DOI: 10.1016/S0140-6736(03)12267-2
51. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63. DOI: 10.1007/s001250051594
52. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592–6. DOI: 10.2337/dc11-0943
53. Tudor SM, Hamman RF, Baron A, Johnson DW, Shetterly SM. Incidence and progression of diabetic retinopathy in Hispanics and non-Hispanic whites with type 2 diabetes. San Luis Valley Diabetes Study, Colorado. Diabetes Care. 1998;21(1):53–61. DOI: 10.2337/diacare.21.1.53
54. Varma R, Choudhury F, Klein R, Chung J, Torres M, Azen SP. Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2010;149(5):752–61. e1-3. DOI: 10.1016/j.ajo.2009.11.014
55. Lee ET, Lee VS, Kingsley RM, Lu M, Russell D, Asal NR, et al. Diabetic retinopathy in Oklahoma Indians with NIDDM. Incidence and risk factors. Diabetes Care. 1992;15(11):1620–7. DOI: 10.2337/diacare.15.11.1620
56. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond). 2007;21(4):465–71.
57. Leske MC, Wu SY, Hennis A, Nemesure B, Schachat AP, Hyman L, et al. Nine-year incidence of diabetic retinopathy in the Barbados Eye Studies. Arch Ophthalmol. 2006;124(2):250–5. DOI: 10.1001/archopht.124.2.250
58. Tapp RJ, Zimmet PZ, Harper CA, McCarty DJ, Chitson P, Tonkin AM, et al. Six year incidence and progression of diabetic retinopathy: results from the Mauritius diabetes complication study. Diabetes Res Clin Pract. 2006;73(3):298–303. DOI: 10.1016/j.diabres.2006.02.009
59. Salinero-Fort MA, San Andres-Rebollo FJ, de Burgos-Lunar C, Arrieta-Blanco FJ, Gomez-Campelo P. Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study. PLoS One. 2013;8(10):e76417. DOI: 10.1371/journal.pone.0076417
60. Tam VH, Lam EP, Chu BC, Tse KK, Fung LM. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. J Diabetes Complications. 2009;23(3):185–93. DOI: 10.1016/j.jdiacomp.2008.03.001
61. Song H, Liu L, Sum R, Fung M, Yap MK. Incidence of diabetic retinopathy in a Hong Kong Chinese population. Clin Exp Optom. 2011;94(6):563–7. DOI: 10.1111/j.1444-0938.2011.00628.x
62. Kawasaki R, Tanaka S, Tanaka S, Yamamoto T, Sone H, Ohashi Y, et al. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011;54(9):2288–94. DOI: 10.1007/s00125-011-2199-0
63. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):823–33.
64. Al-Rubeaan K, Abu El-Asrar AM, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, et al. Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. Acta Ophthalmol. 2015;93(2):e140–7. DOI: 10.1111/aos.12532
65. Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M, et al. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Res Clin Pract. 2012;98(2):329–37. DOI: 10.1016/j.diabres.2012.09.006
66. Dutra Medeiros M, Mesquita E, Papoila AL, Genro V, Raposo JF. First diabetic retinopathy prevalence study in Portugal: RETINODIAB Study-Evaluation of the screening programme for Lisbon and Tagus Valley region. Br J Ophthalmol. 2015 doi: 10.1136/bjophthalmol-2015-306727 [Epub ahead of print].
67. Nathoo N, Ng M, Rudnisky CJ, Tennant MT. The prevalence of diabetic retinopathy as identified by teleophthalmology in rural Alberta. Can J Ophthalmol. 2010;45(1):28–32. DOI: 10.3129/i09-220
68. Esteves JF, Kramer CK, Azevedo MJ, Stolz AP, Roggia MF, Larangeira A, et al. Prevalence of diabetic retinopathy in patients with type 1 diabetes mellitus. Rev Assoc Med Bras. 2009;55(3):268–73. DOI: 10.1590/S0104-42302009000300017
69. Villena JE, Yoshiyama CA, Sanchez JE, Hilario NL, Merin LM. Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telescreening program. Rev Panam Salud Publica. 2011;30(5):408–14.
70. Thomas RL, Distiller L, Luzio SD, Chowdhury SR, Melville VJ, Kramer B, et al. Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa. Diabetes Care. 2013;36(2):336–41. DOI: 10.2337/dc12-0683
71. Kaidonis G, Mills RA, Landers J, Lake SR, Burdon KP, Craig JE. Review of the prevalence of diabetic retinopathy in Indigenous Australians. Clin Experiment Ophthalmol. 2014;42(9):875–82. DOI: 10.1111/ceo.12338
72. Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2011;7:CD008081.
73. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497–503. DOI: 10.1016/j.ophtha.2008.10.016
74. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346–54. DOI: 10.1007/s11892-012-0283-6
75. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence of diabetic retinopathy. The Beijing Eye Study 2001/2011. PLoS One. 2014;9(10):e111320. DOI: 10.1371/journal.pone.0111320
76. Kajiwara A, Miyagawa H, Saruwatari J, Kita A, Sakata M, Kawata Y, et al. Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: a clinic-based retrospective longitudinal study. Diabetes Res Clin Pract. 2014;103(3):e7–10. DOI: 10.1016/j.diabres.2013.12.043
77. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, Plana-Gil N, Soler-Lluis N, Mendez-Marin I, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract. 2011;94(1):126–32. DOI: 10.1016/j.diabres.2011.07.004
78. Olsen BS, Sjolie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18(3):160–4. DOI: 10.1016/S1056-8727(03)00073-4
79. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care. 2003;26(4):1224–9. DOI: 10.2337/diacare.26.4.1224
80. Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH. Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia. 2011;54(8):1992–9. DOI: 10.1007/s00125-011-2144-2
81. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23(6):532–43. DOI: 10.1053/S0270-9295(03)00132-3
82. Egan AM, McVicker L, Heerey A, Carmody L, Harney F, Dunne FP. Diabetic retinopathy in pregnancy: a population-based study of women with pregestational diabetes. J Diabetes Res. 2015;2015:310239. doi:10.1155/2015/310239. DOI: 10.1155/2015/310239
83. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23(8):1084–91. DOI: 10.2337/diacare.23.8.1084
84. Ringholm L, Vestgaard M, Laugesen CS, Juul A, Damm P, Mathiesen ER. Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes. Growth Horm IGF Res. 2011;21(1):25–30. DOI: 10.1016/j.ghir.2010.12.001
85. Kastelan S, Tomic M, Pavan J, Oreskovic S. Maternal immune system adaptation to pregnancy--a potential influence on the course of diabetic retinopathy. Reprod Biol Endocrinol. 2010;8:124. DOI: 10.1186/1477-7827-8-124
86. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736–43. DOI: 10.1016/S0140-6736(08)60343-8
87. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902–16. DOI: 10.1001/jama.298.8.902
88. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86.
89. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381–9.
90. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874–86.
91. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126(12):1707–15. DOI: 10.1001/archopht.126.12.1707
92. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631–42. DOI: 10.2337/db14-0930
93. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of retinopathy at 20 years after onset in younger-onset type 1 diabetes using mean metabolic memory-free HbA1c values: the importance of using HbA1c data of total, not partial, diabetes duration. Diabetes Care. 2013;36(11):3812–4. DOI: 10.2337/dc13-0532
94. Smith-Palmer J, Brandle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273–84. DOI: 10.1016/j.diabres.2014.06.007
95. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. DOI: 10.1056/NEJMoa0802987
96. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. DOI: 10.1056/NEJMoa0802743
97. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2:CD009122.
98. Jin P, Peng J, Zou H, Wang W, Fu J, Shen B, et al. The 5-year onset and regression of diabetic retinopathy in Chinese type 2 diabetes patients. PLoS One. 2014;9(11):e113359. DOI: 10.1371/journal.pone.0113359
99. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–13.
100. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–76. DOI: 10.1056/NEJMoa0806359
101. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394–402. DOI: 10.1016/S0140-6736(08)61412-9
102. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–93. DOI: 10.1016/S0140-6736(08)61411-7
103. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.
104. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64. DOI: 10.1001/jama.2011.860
105. Sheely D, Jialal I. Strategies to lower low-density lipoprotein cholesterol in metabolic syndrome: averting the diabetes risk. Metab Syndr Relat Disord. 2013;11(3):149–51. DOI: 10.1089/met.2013.1503
106. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–97. DOI: 10.1016/S0140-6736(07)61607-9
107. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44. DOI: 10.1056/NEJMoa1001288
108. Massin P, Peto T, Ansquer JC, Aubonnet P, Macu FENSIFT. Effects of fenofibric acid on diabetic macular edema: the MacuFen study. Ophthalmic Epidemiol. 2014;21(5):307–17. DOI: 10.3109/09286586.2014.949783
109. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22(1):55–61. DOI: 10.1097/MOL.0b013e328341a5a8
110. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52(2):180–95. DOI: 10.1016/j.survophthal.2006.12.003
111. Henricsson M, Nystrom L, Blohme G, Ostman J, Kullberg C, Svensson M, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26(2):349–54. DOI: 10.2337/diacare.26.2.349
112. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24(2):284–9. DOI: 10.2337/diacare.24.2.284
113. Lu J, Hou X, Zhang L, Jiang F, Hu C, Bao Y, et al. Association between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. Acta Diabetol. 2015;52(4):701–8. DOI: 10.1007/s00592-014-0711-y
114. Rooney D, Lye WK, Tan G, Lamoureux EL, Ikram MK, Cheng CY, et al. Body mass index and retinopathy in Asian populations with diabetes mellitus. Acta Diabetol. 2015;52(1):73–80. DOI: 10.1007/s00592-014-0602-2
115. Rudrappa S, Warren G, Idris I. Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. Br J Ophthalmol. 2012;96(12):1535. DOI: 10.1136/bjophthalmol-2012-301991
116. Mason RH, West SD, Kiire CA, Groves DC, Lipinski HJ, Jaycock A, et al. High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina. 2012;32(9):1791–8.
117. Cheung D, Switzer NJ, Ehmann D, Rudnisky C, Shi X, Karmali S. The impact of bariatric surgery on diabetic retinopathy: a systematic review and meta-analysis. Obes Surg. 2015;25(9):1604–9. DOI: 10.1007/s11695-014-1539-9
118. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–58. DOI: 10.1016/j.preteyeres.2011.05.002
119. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. Diabetologia. 2005;48(2):370–8. DOI: 10.1007/s00125-004-1628-8
120. Nguyen TT, Alibrahim E, Islam FM, Klein R, Klein BE, Cotch MF, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32(9):1704–9. DOI: 10.2337/dc09-0102
121. Lim LS, Tai ES, Mitchell P, Wang JJ, Tay WT, Lamoureux E, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4458–63. DOI: 10.1167/iovs.09-4939
122. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–9, 1149.e1-10. doi: 10.1016/j.ophtha.2008.06.015.
123. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245–51. DOI: 10.1001/archophthalmol.2008.610
124. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007;13(10):2825–30. DOI: 10.1158/1078-0432.CCR-06-2416
125. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24(2):87–92. DOI: 10.1080/08820530902800330
126. Colucciello M. Current intravitreal pharmacologic therapies for diabetic macular edema. Postgrad Med. 2015;127(6):640–53. DOI: 10.1080/00325481.2015.1052523
127. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25. DOI: 10.1016/j.ophtha.2011.01.031
128. Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, et al. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol. 2015;133(5):589–97. DOI: 10.1001/jamaophthalmol.2015.186
129. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. DOI: 10.1056/NEJMoa1414264
130. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77. e35. DOI: 10.1016/j.ophtha.2010.02.031
131. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris 3rd FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14. DOI: 10.1016/j.ophtha.2010.12.033
132. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54(9):1847–56. DOI: 10.1007/s10620-008-0585-3
133. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes. Int J Tissue React. 2002;24(4):137–42.
134. Suganami E, Takagi H, Ohashi H, Suzuma K, Suzuma I, Oh H, et al. Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes. 2004;53(9):2443–8. DOI: 10.2337/diabetes.53.9.2443
135. Gariano RF, Nath AK, D’Amico DJ, Lee T, Sierra-Honigmann MR. Elevation of vitreous leptin in diabetic retinopathy and retinal detachment. Invest Ophthalmol Vis Sci. 2000;41(11):3576–81.
136. Dossarps D, Petit JM, Guiu B, Cercueil JP, Duvillard L, Bron AM, et al. Body fat distribution and adipokine secretion are not associated with diabetic retinopathy in patients with type 2 diabetes mellitus. Ophthalmic Res. 2014;51(1):42–5. DOI: 10.1159/000355323
137. Sari R, Balci MK, Apaydin C. The relationship between plasma leptin levels and chronic complication in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord. 2010;8(6):499–503. DOI: 10.1089/met.2009.0127
138. Omae T, Nagaoka T, Tanano I, Yoshida A. Adiponectin-induced dilation of isolated porcine retinal arterioles via production of nitric oxide from endothelial cells. Invest Ophthalmol Vis Sci. 2013;54(7):4586–94. DOI: 10.1167/iovs.13-11756
139. Omae T, Nagaoka T, Yoshida A. Relationship between retinal blood flow and serum adiponectin concentrations in patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2015;56(6):4143–9. DOI: 10.1167/iovs.15-16447
140. Srinivasan V, Sulochana KN. Effect of adiponectin on expression of vascular endothelial growth factor and pigment epithelium-derived factor: an in vitro study. Indian J Pharmacol. 2015;47(1):117–20. DOI: 10.4103/0253-7613.150376
141. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects - (CURES-133). Clin Biochem. 2015;48(1–2):33–8. DOI: 10.1016/j.clinbiochem.2014.10.009
142. Zietz B, Buechler C, Kobuch K, Neumeier M, Scholmerich J, Schaffler A. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008;116(9):532–6. DOI: 10.1055/s-2008-1058086
143. Yilmaz MI, Sonmez A, Acikel C, Celik T, Bingol N, Pinar M, et al. Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur J Endocrinol. 2004;151(1):135–40. DOI: 10.1530/eje.0.1510135
144. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9(4):315–27. DOI: 10.1007/s11154-008-9090-4
145. Robison Jr WG, Jacot JL, Katz ML, Glover JP. Retinal vascular changes induced by the oxidative stress of alpha-tocopherol deficiency contrasted with diabetic microangiopathy. J Ocul Pharmacol Ther. 2000;16(2):109–20. DOI: 10.1089/jop.2000.16.109
146. Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal. 2005;7(11–12):1581–87. DOI: 10.1089/ars.2005.7.1581
147. Naruse R, Suetsugu M, Terasawa T, Ito K, Hara K, Takebayashi K, et al. Oxidative stress and antioxidative potency are closely associated with diabetic retinopathy and nephropathy in patients with type 2 diabetes. Saudi Med J. 2013;34(2):135–41.
148. Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid Med Cell Longev. 2014;2014:752387. DOI: 10.1155/2014/752387
149. Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm Biotechnol. 2011;12(3):362–8. DOI: 10.2174/138920111794480534
150. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs. 1999;8(12):2095–119. DOI: 10.1517/13543784.8.12.2095
151. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54(7):2188–97. DOI: 10.2337/diabetes.54.7.2188
152. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113(12):2221–30. DOI: 10.1016/j.ophtha.2006.07.032
153. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24(1):32–40. DOI: 10.1159/000075627
154. Brzovic-Saric V, Landeka I, Saric B, Barberic M, Andrijasevic L, Cerovski B, et al. Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients. Mol Vis. 2015;21:649–64.
155. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92(4):548–51. DOI: 10.1136/bjo.2007.130542
156. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12(10):976–89. DOI: 10.1016/j.autrev.2013.02.004
157. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, et al. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci. 2007;48(5):2327–34. DOI: 10.1167/iovs.06-1210
158. Ren Z, Li W, Zhao Q, Ma L, Zhu J. The impact of 1,25-dihydroxy vitamin D3 on the expressions of vascular endothelial growth factor and transforming growth factor-beta(1) in the retinas of rats with diabetes. Diabetes Res Clin Pract. 2012;98(3):474–80. DOI: 10.1016/j.diabres.2012.09.028
159. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, et al. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care. 2011;34(6):1400–2. DOI: 10.2337/dc11-0103
160. Shimo N, Yasuda T, Kaneto H, Katakami N, Kuroda A, Sakamoto F, et al. Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients. Diabetes Res Clin Pract. 2014;106(2):e41–3. DOI: 10.1016/j.diabres.2014.08.005
161. He R, Shen J, Liu F, Zeng H, Li L, Yu H, et al. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med. 2014;31(12):1657–64. DOI: 10.1111/dme.12581
162. Jee D, Han K, Kim EC. Inverse association between high blood 25-hydroxyvitamin D levels and diabetic retinopathy in a representative Korean population. PLoS One. 2014;9(12):e115199. DOI: 10.1371/journal.pone.0115199
163. Alcubierre N, Valls J, Rubinat E, Cao G, Esquerda A, Traveset A, et al. Vitamin D deficiency is associated with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus. J Diabetes Res. 2015;2015:374178. DOI: 10.1155/2015/374178
164. Patel S, Chen H, Tinkham NH, Zhang K. Genetic susceptibility of diabetic retinopathy. Curr Diab Rep. 2008;8(4):257–62. DOI: 10.1007/s11892-008-0046-6
165. Hallman DM, Huber Jr JC, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005;28(5):1163–8. DOI: 10.2337/diacare.28.5.1163
166. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57(8):2176–80. DOI: 10.2337/db07-1495
167. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839–45. DOI: 10.1167/iovs.07-1633
168. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(11):1829–39.
169. Wang H, Cheng JW, Zhu LS, Wei RL, Cai JP, Li Y, et al. Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. Ophthalmic Res. 2014;52(1):1–8. DOI: 10.1159/000357110
170. Han L, Zhang L, Xing W, Zhuo R, Lin X, Hao Y, et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case–control studies. J Diabetes Res. 2014;2014:805801. DOI: 10.1155/2014/805801
171. El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin Experiment Ophthalmol. 2014;42(4):369–78. DOI: 10.1111/ceo.12182
172. Kaidonis G, Burdon KP, Gillies MC, Abhary S, Essex RW, Chang JH, et al. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. Ophthalmology. 2015. doi:10.1016/j.ophtha.2015.05.004. DOI: 10.1016/j.ophtha.2015.05.004
173. Zhou M, Zhang P, Xu X, Sun X. The relationship between aldose reductase C106T polymorphism and diabetic retinopathy: an updated meta-analysis. Invest Ophthalmol Vis Sci. 2015;56(4):2279–89. DOI: 10.1167/iovs.14-16279
174. El-Bab MF, Zaki NS, Mojaddidi MA, Al-Barry M, El-Beshbishy HA. Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes. Int J Gen Med. 2013;6:799–806. DOI: 10.2147/IJGM.S40665
175. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Slama G, et al. Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia. 2002;45(3):436–42. DOI: 10.1007/s00125-001-0769-2
176. Taverna MJ, Selam JL, Slama G. Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes. J Clin Endocrinol Metab. 2005;90(8):4803–8. DOI: 10.1210/jc.2004-2407
177. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472–81. DOI: 10.1093/hmg/ddr121
178. Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642–8. DOI: 10.1016/j.ophtha.2010.07.020
179. Sheu WH, Kuo JZ, Lee IT, Hung YJ, Lee WJ, Tsai HY, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22(15):3165–73. DOI: 10.1093/hmg/ddt161
180. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS One. 2014;9(11):e111715. DOI: 10.1371/journal.pone.0111715
181. Wang WJ, Tay HG, Soni R, Perumal GS, Goll MG, Macaluso FP, et al. CEP162 is an axoneme-recognition protein promoting ciliary transition zone assembly at the cilia base. Nat Cell Biol. 2013;15(6):591–601. DOI: 10.1038/ncb2739
182. Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98(5):629–38. DOI: 10.1136/bjophthalmol-2013-304033
183. Keeffe J, Taylor HR, Fotis K, Pesudovs K, Flaxman SR, Jonas JB, et al. Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010. Br J Ophthalmol. 2014;98(5):586–91. DOI: 10.1136/bjophthalmol-2013-304050
184. Naidoo K, Gichuhi S, Basanez MG, Flaxman SR, Jonas JB, Keeffe J, et al. Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010. Br J Ophthalmol. 2014;98(5):612–8. DOI: 10.1136/bjophthalmol-2013-304081
185. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2010;117(1):63–70. DOI: 10.1016/j.ophtha.2009.06.051
186. Arora S, Kolb S, Goyder E, McKibbin M. Trends in the incidence of visual impairment certification secondary to diabetic retinopathy in the Leeds metropolitan area, 2005–2010. Diabet Med. 2012;29(7):e112–6. DOI: 10.1111/j.1464-5491.2012.03619.x
187. Hall HN, Chinn DJ, Sinclair A, Styles CJ. Epidemiology of blindness attributable to diabetes in Scotland: change over 20 years in a defined population. Diabet Med. 2013;30(11):1349–54. DOI: 10.1111/dme.12223
188. Rani PK, Raman R, Gella L, Kulothungan V, Sharma T. Prevalence of visual impairment and associated risk factors in subjects with type II diabetes mellitus: sankara nethralaya diabetic retinopathy epidemiology and molecular genetics study (SN-DREAMS, report 16). Middle East Afr J Ophthalmol. 2012;19(1):129–34. DOI: 10.4103/0974-9233.92129
189. Chiang PP, Lamoureux EL, Zheng Y, Tay WT, Mitchell P, Wang JJ, et al. Frequency and risk factors of non-retinopathy ocular conditions in people with diabetes: the Singapore Malay Eye Study. Diabet Med. 2013;30(2):e32–40. DOI: 10.1111/dme.12053
190. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Am J Ophthalmol. 1995;119(3):295–300. DOI: 10.1016/S0002-9394(14)71170-5
191. Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, Kim SJ, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol. 2013;131(7):870–9. DOI: 10.1001/jamaophthalmol.2013.2313
192. Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care. 2008;31(9):1905–12. DOI: 10.2337/dc08-0342
193. Goto A, Inatani M, Inoue T, Awai-Kasaoka N, Takihara Y, Ito Y, et al. Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. J Glaucoma. 2013;22(7):572–6. DOI: 10.1097/IJG.0b013e31824d514a
194. Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3). Invest Ophthalmol Vis Sci. 2014;55(10):6547–53. DOI: 10.1167/iovs.14-15001
195. Lee WJ, Sobrin L, Kang MH, Seong M, Kim YJ, Yi JH, et al. Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye (Lond). 2014;28(9):1119–25. DOI: 10.1038/eye.2014.130
196. Grunwald JE, Alexander J, Ying GS, Maguire M, Daniel E, Whittock-Martin R, et al. Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. Arch Ophthalmol. 2012;130(9):1136–44. DOI: 10.1001/archophthalmol.2012.1800
197. Romero P, Baget M, Mendez I, Fernandez J, Salvat M, Martinez I. Diabetic macular edema and its relationship to renal microangiopathy: a sample of Type I diabetes mellitus patients in a 15-year follow-up study. J Diabetes Complications. 2007;21(3):172–80. DOI: 10.1016/j.jdiacomp.2006.07.008
198. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Relationship of diabetic retinopathy with coronary artery disease in Asian Indians with type 2 diabetes: the Chennai Urban Rural Epidemiology Study (CURES) Eye Study--3. Diabetes Technol Ther. 2015;17(2):112–8. DOI: 10.1089/dia.2014.0141
199. Cosson E, Nguyen MT, Chanu B, Balta S, Takbou K, Valensi P. The report of male gender and retinopathy status improves the current consensus guidelines for the screening of myocardial ischemia in asymptomatic type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23(6):557–65. DOI: 10.1016/j.numecd.2012.01.009
200. Ricardo AC, Grunwald JE, Parvathaneni S, Goodin S, Ching A, Lash JP. Retinopathy and CKD as predictors of all-cause and cardiovascular mortality: National Health and Nutrition Examination Survey (NHANES) 1988–1994. Am J Kidney Dis. 2014;64(2):198–203. DOI: 10.1053/j.ajkd.2014.01.437
201. Chen YW, Wang YY, Zhao D, Yu CG, Xin Z, Cao X, et al. High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. PLoS One. 2015;10(3):e0122022. DOI: 10.1371/journal.pone.0122022
202. Abougalambou SS, Abougalambou AS. Risk factors associated with diabetic retinopathy among type 2 diabetes patients at teaching hospital in Malaysia. Diabetes Metab Syndr. 2015;9(2):98–103. DOI: 10.1016/j.dsx.2014.04.019
203. Chiang PP, Lamoureux EL, Cheung CY, Sabanayagam C, Wong W, Tai ES, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Invest Ophthalmol Vis Sci. 2011;52(10):7586–92. DOI: 10.1167/iovs.11-7698
204. Zheng Y, Lamoureux EL, Chiang PC, Anuar AR, Ding J, Wang JJ, et al. Language barrier and its relationship to diabetes and diabetic retinopathy. BMC Public Health. 2012;12:781. DOI: 10.1186/1471-2458-12-781
205. Katulanda P, Ranasinghe P, Jayawardena R. Prevalence of retinopathy among adults with self-reported diabetes mellitus: the Sri Lanka diabetes and Cardiovascular Study. BMC Ophthalmol. 2014;14:100. DOI: 10.1186/1471-2415-14-100
206. Schellini SA, Carvalho GM, Rendeiro FS, Padovani CR, Hirai FE. Prevalence of diabetes and diabetic retinopathy in a Brazilian population. Ophthalmic Epidemiol. 2014;21(1):33–8. DOI: 10.3109/09286586.2013.868004
207. Papali’i-Curtin AT, Dalziel DM. Prevalence of diabetic retinopathy and maculopathy in Northland, New Zealand: 2011–2012. N Z Med J. 2013;126(1383):20–8.
208. Win Tin ST, Kenilorea G, Gadabu E, Tasserei J, Colagiuri R. The prevalence of diabetes complications and associated risk factors in Pacific Islands countries. Diabetes Res Clin Pract. 2014;103(1):114–8. DOI: 10.1016/j.diabres.2013.09.017
209. Tsugawa Y, Takahashi O, Meigs JB, Davis RB, Imamura F, Fukui T, et al. New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. Diabetes. 2012;61(12):3280–4. DOI: 10.2337/db12-0103
210. Ahmed KR, Karim MN, Bhowmik B, Habib SH, Bukht MS, Ali L, et al. Incidence of diabetic retinopathy in Bangladesh: a 15-year follow-up study. J Diabetes. 2012;4(4):386–91. DOI: 10.1111/j.1753-0407.2012.00208.x
211. Manaviat MR, Rashidi M, Afkhami-Ardekani M. Four years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol. 2008;18(4):572–7.
212. Janghorbani M, Amini M, Ghanbari H, Safaiee H. Incidence of and risk factors for diabetic retinopathy in Isfahan, Iran. Ophthalmic Epidemiol. 2003;10(2):81–95. DOI: 10.1076/opep.10.2.81.13893
213. Perol J, Balkau B, Guillausseau PJ, Massin P. A study of the 3-year incidence of diabetic retinopathy in a French diabetic population seen at Lariboisiere Hospital, Paris. Diabetes Metab. 2012;38(3):225–9. DOI: 10.1016/j.diabet.2012.01.001
214. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1519–26. DOI: 10.1007/s00417-008-0884-6
215. Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40. DOI: 10.1001/jamaophthalmol.2014.2854
216. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, demographics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort. J Ophthalmol. 2012;2012:159167.